Linking Psoriasis Severity to Cardiovascular Risk: The Role of Systemic Inflammation

The interplay between psoriasis and cardiovascular disease has been a topic of intense research and growing clinical concern over the past decade. While observational studies and registry data have consistently shown an increased risk of cardiovascular disease and cardiovascular mortality among patients with moderate to severe psoriasis, the biological mechanisms underlying this association have remained elusive. One prevailing hypothesis is that inflammatory signals originating in psoriatic skin enter the circulation, fueling systemic inflammation that contributes to the development and progression of atherosclerosis. 

In this well-conducted study, Svedbom et al. leverage two complementary cohorts to tackle this long-standing question. The Psoriasis Atherosclerosis and Cardiometabolic Disease Initiative (PACI) in the United States assessed subclinical coronary atherosclerosis (non-calcified coronary burden). At the same time, the Stockholm Psoriasis Cohort (SPC) in Sweden followed incident psoriasis cases for cardiovascular events. In both cohorts, higher PASI scores were significantly associated with elevated levels of GlycA, a stable biomarker of systemic inflammation. 

The authors used mediation models to assess whether systemic inflammation explained the association between psoriasis severity and cardiovascular disease. Their findings are striking: GlycA mediated approximately 17% of the association with subclinical coronary plaque burden and 37% of the association with clinical cardiovascular events. In the SPC cohort, the association between PASI and cardiovascular events became statistically nonsignificant after adjusting for GlycA, reinforcing the mediating role of systemic inflammation. 

This work adds biological plausibility to what clinicians observe daily: patients with more severe psoriasis exhibit greater systemic inflammatory burden, which may increase their cardiovascular risk. It also reinforces the potential of GlycA as a translational biomarker that could bridge dermatology and cardiology. 

While the findings are compelling, several questions remain. First, the mediation proportion suggests that systemic inflammation is only part of the story; what other mechanisms are at play? Metabolic dysregulation, insulin resistance, endothelial dysfunction, and treatment effects may all contribute. Recent Mendelian randomization studies suggest that metabolic syndrome and related cardiometabolic alterations may predispose to psoriasis, rather than the reverse. Similarly, genetic liability to cardiovascular disease, particularly coronary artery disease and stroke, has been associated with increased risk of psoriasis, but not vice versa. These findings challenge the notion of a unidirectional, skin-driven model of systemic inflammation. Instead, they underscore the possibility that shared genetic pathways and underlying metabolic dysfunction may simultaneously predispose individuals to both psoriasis and atherosclerosis. Secondly, while GlycA appears promising as a research and possibly clinical tool, its availability and integration into clinical practice are still limited. 

Importantly, these findings support the rationale for aggressive management of psoriasis to control skin symptoms and mitigate cardiovascular risk. Whether biologic therapies targeting IL-17, IL-23, or TNF can reduce CV outcomes by attenuating systemic inflammation remains a critical research question. While some evidence suggests a potential benefit, the data remain limited and largely indirect. Prospective trials designed with cardiovascular endpoints, or at least long-term real-world follow-up in registries, are needed to validate this hypothesis. 

This study elegantly links skin disease severity to cardiovascular outcomes through systemic inflammation. It underscores the importance of viewing psoriasis as a systemic disease and strengthens the case for a multidisciplinary, comorbidity-conscious approach to patient care. As we continue to refine our understanding of immune-mediated diseases, this work is a timely and significant contribution to the field.